云南白药
(000538)
| 流通市值：989.75亿 | | | 总市值：996.15亿 |
| 流通股本：17.73亿 | | | 总股本：17.84亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 30,654,214,209.01 | 21,257,102,896.02 | 10,841,237,721.29 | 40,033,300,814.72 |
| 营业收入 | 30,654,214,209.01 | 21,257,102,896.02 | 10,841,237,721.29 | 40,033,300,814.72 |
| 二、营业总成本 | 26,074,760,939.86 | 17,836,286,155.07 | 8,751,171,876.26 | 35,206,797,286.5 |
| 营业成本 | 21,439,589,799.52 | 14,697,868,069.29 | 7,420,335,309.2 | 28,864,766,205.1 |
| 税金及附加 | 168,628,336.49 | 125,773,653.15 | 53,385,295.89 | 243,117,369.44 |
| 销售费用 | 3,715,299,786.11 | 2,516,371,857.04 | 1,070,132,434.21 | 4,879,502,036.91 |
| 管理费用 | 555,274,908.29 | 363,479,043.45 | 156,401,058.22 | 1,037,553,483.87 |
| 研发费用 | 234,998,200.97 | 155,900,139.57 | 60,122,221.9 | 337,413,301.03 |
| 财务费用 | -39,030,091.52 | -23,106,607.43 | -9,204,443.16 | -155,555,109.85 |
| 其中:利息费用 | 15,215,722.1 | 10,739,501.71 | 6,186,412.99 | 63,177,001.07 |
| 其中:利息收入 | 75,016,226.69 | 49,581,264.78 | 20,207,465.3 | 221,210,259.84 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 81,760,362.06 | 70,037,496.76 | 40,964,635.95 | 136,837,009.94 |
| 加:投资收益 | 951,171,248.8 | 839,628,716.65 | 222,556,306.38 | 776,937,495.06 |
| 资产处置收益 | 3,036,533.62 | 2,552,729.83 | 81,785.84 | 490,651.65 |
| 资产减值损失(新) | -66,216,984.74 | -41,743,184.35 | -23,107,745.76 | -91,230,709.62 |
| 信用减值损失(新) | -13,090,132.2 | -98,382,642.61 | -90,587,139.08 | -39,925,926.62 |
| 其他收益 | 68,938,519.46 | 27,406,398.49 | 15,331,762.07 | 102,009,773.65 |
| 四、营业利润 | 5,605,052,816.15 | 4,220,316,255.72 | 2,255,305,450.43 | 5,711,621,822.28 |
| 加:营业外收入 | 18,588,012.77 | 17,525,440.99 | 5,038,390.96 | 15,483,338.73 |
| 减:营业外支出 | 8,542,285.23 | 5,969,854.92 | 4,362,446.39 | 42,385,497.02 |
| 五、利润总额 | 5,615,098,543.69 | 4,231,871,841.79 | 2,255,981,395 | 5,684,719,663.99 |
| 减:所得税费用 | 825,928,468.27 | 587,271,873.85 | 328,470,191.51 | 917,647,303.71 |
| 六、净利润 | 4,789,170,075.42 | 3,644,599,967.94 | 1,927,511,203.49 | 4,767,072,360.28 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 4,789,170,075.42 | 3,644,599,967.94 | 1,927,511,203.49 | 4,767,072,360.28 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 4,777,119,657.47 | 3,632,911,303.12 | 1,934,639,584.6 | 4,749,415,499.55 |
| 少数股东损益 | 12,050,417.95 | 11,688,664.82 | -7,128,381.11 | 17,656,860.73 |
| 扣除非经常损益后的净利润 | 4,549,939,286.91 | 3,460,915,449.48 | 1,887,406,845.46 | 4,523,057,538.23 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 2.68 | 2.04 | 1.08 | 2.66 |
| (二)稀释每股收益 | 2.68 | 2.04 | 1.08 | 2.66 |
| 八、其他综合收益 | 3,052,405.37 | 4,613,102.15 | -122,538.7 | -13,441,329.34 |
| 归属于母公司股东的其他综合收益 | 1,788,432.1 | 3,258,451.54 | 28,469.89 | -11,725,184.18 |
| 九、综合收益总额 | 4,792,222,480.79 | 3,649,213,070.09 | 1,927,388,664.79 | 4,753,631,030.94 |
| 归属于母公司股东的综合收益总额 | 4,778,908,089.57 | 3,636,169,754.66 | 1,934,668,054.49 | 4,737,690,315.37 |
| 归属于少数股东的综合收益总额 | 13,314,391.22 | 13,043,315.43 | -7,279,389.7 | 15,940,715.57 |
| 公告日期 | 2025-10-31 | 2025-08-30 | 2025-04-29 | 2025-04-01 |
| 审计意见(境内) | | | | 标准无保留意见 |